BioMedNewsBreaks

TuesdayApr 22, 2025 3:10 pm

BioMedNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement

BioVaxys (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) and SpayVac-for-Wildlife announced an expansion of the fields of use in the current license agreement to include commercial aquaculture and the farm-raised fish market. With this expansion, SpayVac’s markets now include its no-booster fertility-control vaccines for aquaculture and overabundant feral/wild/invasive and select production and companion animals, which significantly increases its global revenue potential. “This presents a substantial addressable market for SpayVac’s contraceptive vaccines, which are being developed as an alternative to triploidy—a form of genetic manipulation commonly used in aquaculture to induce sterility,” said SpayVac-for-Wildlife CEO Thomas D’Orazio. “With only a single dose…

Continue Reading

TuesdayApr 22, 2025 9:30 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting Cancer Immunotherapy Pipeline

Calidi Biotherapeutics (NYSE American: CLDI) will host a live investor webinar on April 24, 2025, at 4:15 p.m. ET, featuring its new Chief Medical Officer, Dr. Guy Travis Clifton. The event will spotlight Calidi’s stem cell-based delivery platforms for oncolytic virus therapies, including the FDA-cleared CLD-201, which is advancing toward trials for solid tumors. Additional program updates will include CLD-400 for metastatic and lung cancer and CLD-101 for high-grade gliomas. A live Q&A will follow the presentation. To view the full press release, visit: https://ibn.fm/0we8c About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to…

Continue Reading

ThursdayApr 17, 2025 10:27 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Named EY Entrepreneur of the Year 2025 Finalist in Established Category 

Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan has been named a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. Sheridan is one of 27 Irish entrepreneurs recognized for their leadership and impact, with finalists selected from across 24 companies generating more than €1 billion in annual revenue.  Sheridan is being recognized for his role in transforming Nutriband from an early-stage startup into a U.S.-listed life sciences company focused on transdermal drug delivery and abuse-deterrent technologies. The company’s lead product, AVERSA™, is designed to prevent the misuse and abuse of opioid patches—addressing a critical gap in…

Continue Reading

ThursdayApr 17, 2025 9:25 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors

Calidi Biotherapeutics (NYSE American: CLDI) announced FDA clearance of its Investigational New Drug application for CLD-201, an allogeneic stem cell-based virotherapy targeting solid tumors including breast cancer, head and neck cancer, and soft tissue sarcoma. Backed by preclinical data showing immune system evasion and potent tumor-killing ability, CLD-201 is now cleared to enter clinical development. The therapy combines adipose-derived stem cells with oncolytic vaccinia virus, representing a novel immunotherapeutic approach for hard-to-treat cancers. To view the full press release, visit: https://ibn.fm/qhTKp About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel…

Continue Reading

WednesdayApr 16, 2025 12:20 pm

BioMedNewsBreaks – ProPhase Labs Inc. (NASDAQ: PRPH) Closes $23.6M Sale to Focus on Core Businesses

ProPhase (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, earlier this year announced the closing of the sale of its wholly owned subsidiaries, Pharmaloz Manufacturing Inc. and Pharmaloz Real Estate Holdings Inc. (collectively “Pharmaloz” or “PMI”), to a private equity group based in Houston, Texas. The transaction’s aggregate deal was valued at approximately $23.6 million, which immediately bolstered ProPhase’s balance sheet and liquidity by eliminating over $20 million in debt, payables, and other contingent liabilities. Overall, the transaction better positioned ProPhase to focus on its promising and high-value core businesses. To view the full press release, visit https://ibn.fm/7xp1E About…

Continue Reading

TuesdayApr 15, 2025 3:33 pm

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures $3.7M in Warrant Inducement Transaction 

Bluejay (NASDAQ: BJDX) is a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings. The company recently announced its entry into an agreement with institutional investors to exercise existing warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in approximately $3.7 million in gross proceeds. In consideration for the exercise of the existing warrants for cash, the investors received new five-year warrants to purchase the same number of shares at an exercise price of $3.42 per share. Aegis Capital Corp. acted…

Continue Reading

TuesdayApr 15, 2025 8:30 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Secures Military Contract Extension for Iridium PTT Services

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, announced that its subsidiary, Global Telesat Communications Ltd., received a one-year contract extension from an African military customer for wireless connectivity services. The renewal builds on a 2024 deal for Iridium Push-To-Talk (PTT) hardware and airtime services, which marked the largest such contract in company history. The extension includes options for additional hardware and annual service renewals and is not impacted by recent U.S. tariffs. The Iridium Extreme PTT devices are favored for their secure, global communication capabilities in high-demand government, military and enterprise applications. To view the full press release, visit:…

Continue Reading

MondayApr 14, 2025 3:03 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM)

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company today announced interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (“CTCL”).  “We are pleased with these recent study results, giving patients an opportunity to access the therapy in an open-label setting,” said Soligenix CEO and President Christopher J. Schaber. “CTCL is an incredibly difficult to treat orphan disease and remains an area of unmet…

Continue Reading

MondayApr 14, 2025 1:50 pm

BioMedNewsBreaks – Immunic Inc. (NASDAQ: IMUX) Closes $5.1M Registered Direct

Immunic (NASDAQ: IMUX),a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has closed its previously announced registered direct offering of 5,666,667 shares of its common stock, each at a price of $0.90, led by Aberdeen Investments. Immunic secured approximately $5.1 million in gross proceeds, from which it intends to use the net to fund its clinical trials and operations and for other general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as the sole placement agent for the offering. To view the full press release, visit…

Continue Reading

MondayApr 14, 2025 10:09 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Prevails in Legal Dispute With Former CEO 

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative, metabolic and alcohol misuse disorders, announced that a reconsideration motion filed by former CEO Dr. Raza Bokhari was fully dismissed by the Court of Appeal for Ontario. Bokhari, terminated for cause in 2021, had previously lost an arbitration claiming wrongful dismissal, which resulted in a total cost award of approximately C$2.81 million plus interest. Additional court-awarded costs have raised the amount due to over C$3 million. Quantum BioPharma has initiated U.S. collection proceedings, resulting in a judgment entered in its favor by the U.S. District Court for the Eastern District of…

Continue Reading